ZENITH

Official Title

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Study Purpose

To evaluate whether zilebesiran versus placebo reduces the risk of CV death, nonfatal MI, nonfatal stroke, or HF events

Diagnosis

Eligibility

Stable medical treatment and recent medical history (60 days)

Symptomatic Orthostatic Hypotension

Known severe intolerance of certain medications

Any ejection fraction less than 40%

Intervention

Zilebesiran versus placebo